<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663400</url>
  </required_header>
  <id_info>
    <org_study_id>18-00630</org_study_id>
    <nct_id>NCT03663400</nct_id>
  </id_info>
  <brief_title>Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples</brief_title>
  <official_title>Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study enrolling ulcerative colitis patients who initiate
      tofacitinib therapy. Investigators will collect clinical data, blood and stool samples prior
      to initiation of tofacitinib and, at minimum, monthly after the start of therapy. They will
      collect tissue from colonoscopies prior to initiation of therapy and within 6 months on
      therapy. Clinical characteristics and response to treatment will then be associated with
      genotype, blood immune profiles, stool microbiota, and cellular and molecular profiles of the
      biopsies to generate a treatment response model. Using predictors identified in our model, we
      will then attempt to validate the model and findings with the OCTAVE (Pfizer), SPARC (CCF),
      and RISK (CCF) data.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>GWAS analysis pretreatment</measure>
    <time_frame>1 Day</time_frame>
    <description>GWAS analysis by Illumina BeadChip to generate comprehensive genotype data on all 50 patients.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Patients Treated with Tofacitinib</arm_group_label>
    <description>Microbiota profiling by 16S sequencing RNA-seq transcriptional profiling of the blood and biopsy samples Immunological profiling by multi-parameter flow cytometry</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GWAS analysis by Illumina BeadChip</intervention_name>
    <description>will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry</description>
    <arm_group_label>Patients Treated with Tofacitinib</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Microbiota profiling by 16S sequencing RNA seq transcriptional profiling oof blood and biopsy
      Immunological profiling by multi parameter flow cytometry
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18-70 with moderate to severe ulcerative colitis defined as a total mayo score
        between 6 and 12, and an endoscopic subscore of 2 or 3.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Total mayo score between 6 and 12

          -  Endoscopic subscore of 2 or 3

        Exclusion Criteria:

          -  Recent use of antibiotic therapy (&lt;4 weeks)

          -  Current extreme diet (parenteral nutrition, specific carbohydrate diet).

          -  Active infection or malignancy.

          -  Significant underlying liver or renal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hudesman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghoncheh Ghiasian, MPH</last_name>
    <phone>646-501-7822</phone>
    <email>Ghoncheh.Ghiasian@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bhavna Sharma, BS</last_name>
    <email>Bhavna.Sharma@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghoncheh Ghiasian</last_name>
      <email>Ghoncheh.Ghiasian@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>David Hudesman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

